PROSTA-Q Price

Overview

Welcome to Dwaey, specifically on PROSTA-Q page.
This medicine contains an important and useful components, as it consists of
Bromelain 150 GDU, Papain fruit extract , Quercetin , Saw palmetto (Seronea repens) seed extract , Cranberry (Vaccinium oxycoccus) fruit extract , Zinc (as Zinc gluconate)is available in the market in concentration

Name

Bevacizumab

Precaution

Before starting **Bevacizumab**, it is essential to consult a healthcare provider to ensure it is safe for you, especially if you have any pre-existing medical conditions. Some important precautions include: - **Cardiovascular Conditions**: Bevacizumab can increase the risk of **high blood pressure** and may cause heart failure in some patients. People with pre-existing heart problems, such as **hypertension** or **congestive heart failure**, should be closely monitored. - **Bleeding and Clotting Disorders**: Bevacizumab can increase the risk of **bleeding** or **blood clots**. It is important to inform your healthcare provider if you have a history of blood clots, **stroke**, or any bleeding disorders (e.g., **hemophilia**). - **Surgical Procedures**: Since Bevacizumab may impair wound healing, it should be discontinued at least **28 days before surgery** and should not be resumed until **28 days after surgery** to allow for proper healing. - **Gastrointestinal Issues**: Bevacizumab has been associated with the risk of **gastrointestinal perforations** and fistulas, so caution is required in patients with a history of these conditions. - **Pregnancy and Breastfeeding**: Bevacizumab should not be used during pregnancy, as it may harm the developing fetus. It is classified as a Category C drug by the FDA. It is also not recommended during breastfeeding due to potential risks to the infant.

Indication

Bevacizumab is a **monoclonal antibody** that is primarily used in the treatment of various cancers. Its main indications include: - **Colorectal Cancer**: Bevacizumab is often used in combination with chemotherapy for the treatment of **metastatic colorectal cancer** (mCRC), where it helps to inhibit the growth of blood vessels that supply the tumor, thus limiting its growth. - **Non-Small Cell Lung Cancer**: It is used in combination with chemotherapy to treat advanced **non-small cell lung cancer (NSCLC)**. - **Ovarian Cancer**: Bevacizumab is used for treating **advanced ovarian cancer** in combination with chemotherapy. - **Renal Cell Carcinoma**: Bevacizumab may also be used for treating **metastatic renal cell carcinoma** (kidney cancer), typically alongside other chemotherapy agents. - **Glioblastoma**: Bevacizumab is indicated for the treatment of **glioblastoma multiforme** (GBM), a type of brain cancer, after failure of initial chemotherapy. - **Age-Related Macular Degeneration (AMD)**: Bevacizumab is sometimes used off-label to treat **AMD**, a leading cause of vision loss, by inhibiting the abnormal growth of blood vessels in the retina.

Contra indication

Bevacizumab is contraindicated in the following situations: - **Hypersensitivity**: It should not be used in patients who have a known hypersensitivity to **Bevacizumab** or any of its components. - **Severe Uncontrolled Hypertension**: If a patient has severe or poorly controlled **hypertension**, Bevacizumab should not be used due to its potential to further elevate blood pressure. - **Active Bleeding**: Bevacizumab is contraindicated in patients with active **bleeding disorders** or conditions that predispose them to severe bleeding (e.g., active **gastric ulcer** or **hemorrhagic stroke**). - **Recent Major Surgery**: As Bevacizumab can impair wound healing, it is contraindicated in patients who have had recent major surgery or significant trauma. - **Pregnancy**: Bevacizumab is contraindicated during pregnancy due to the risk of harm to the fetus.

Side Effect

Common and severe side effects of **Bevacizumab** include: - **Common Side Effects**: - **Hypertension**: High blood pressure is a common side effect and can often be managed with antihypertensive medications. - **Fatigue**: Patients may experience **tiredness** or **weakness** during treatment. - **Gastrointestinal Issues**: Nausea, **vomiting**, **diarrhea**, or **constipation** are commonly reported. - **Headache**: Some patients may experience headaches, often due to elevated blood pressure. - **Severe Side Effects**: - **Bleeding**: Severe bleeding complications, such as **gastrointestinal bleeding**, **cerebral hemorrhage**, or **nosebleeds**, are possible. - **Gastrointestinal Perforation**: Bevacizumab has been associated with an increased risk of **perforation** in the gastrointestinal tract, which can be life-threatening. - **Wound Healing Complications**: There may be delayed healing of surgical wounds, and in some cases, wound dehiscence or infection can occur. - **Thromboembolic Events**: Bevacizumab can increase the risk of blood clots, including **deep vein thrombosis (DVT)**, **pulmonary embolism (PE)**, or **stroke**. - **Proteinuria**: Some patients may develop kidney-related issues, such as **protein in the urine** or **kidney dysfunction**.

Pregnancy Category ID

3

Mode of Action

Bevacizumab is an **anti-angiogenic** agent that works by inhibiting **vascular endothelial growth factor (VEGF)**. Its mechanism of action involves: - **VEGF Inhibition**: VEGF is a protein that promotes the growth of blood vessels (angiogenesis) to tumors. Bevacizumab binds to VEGF, preventing it from interacting with its receptors on blood vessels, thus inhibiting the formation of new blood vessels that supply nutrients and oxygen to tumors. - **Reduced Tumor Blood Supply**: By blocking VEGF, Bevacizumab **starves** tumors of necessary nutrients, limiting their growth and spread. - **Decreased Tumor Metastasis**: With impaired angiogenesis, tumors are less likely to metastasize, or spread to other parts of the body. - **Enhancing Chemotherapy Efficacy**: By improving the delivery of chemotherapy drugs to the tumor and reducing the pressure inside tumor blood vessels, Bevacizumab may enhance the effects of chemotherapy.

Interaction

Bevacizumab may interact with several other medications, which could affect its safety or efficacy. Important interactions include: - **Chemotherapy Drugs**: When used in combination with certain chemotherapy agents, Bevacizumab can **enhance** their efficacy by reducing tumor blood supply, but it may also increase the risk of **severe side effects** such as **neutropenia** or **thrombocytopenia**. - **Antihypertensive Medications**: Bevacizumab may increase the risk of **hypertension** or **elevated blood pressure**. Therefore, patients taking antihypertensive medications should be monitored closely for changes in blood pressure. - **Anticoagulants**: Combining Bevacizumab with **blood-thinning medications** (e.g., **warfarin**) or **aspirin** can increase the risk of **bleeding**. Close monitoring for signs of bleeding is important. - **Other Angiogenesis Inhibitors**: Bevacizumab should not be used concurrently with other **angiogenesis inhibitors**, as this may increase the risk of **adverse cardiovascular events**.

Pregnancy Category Note

Information not available

Adult Dose

The typical adult dosing regimen for **Bevacizumab** depends on the condition being treated: - **Colorectal Cancer**: **5 mg/kg** every **two weeks** or **7.5 mg/kg** every **three weeks**, administered via intravenous infusion. - **Non-Small Cell Lung Cancer (NSCLC)**: **15 mg/kg** every **three weeks**, administered intravenously. - **Ovarian Cancer**: **15 mg/kg** every **three weeks** when used in combination with chemotherapy. - **Glioblastoma**: **10 mg/kg** every **two weeks**, administered intravenously. - **Age-Related Macular Degeneration** (AMD, off-label use): **1.25 mg** injected into the eye, generally administered every **four weeks**.

Child Dose

**Bevacizumab** is not typically recommended for use in children unless specifically prescribed in clinical settings. The safety and efficacy of Bevacizumab in pediatric patients have not been fully established. Pediatric dosing would be based on weight, specific condition, and medical supervision, and typically requires specialized management in a hospital setting.

Renal Dose

Bevacizumab does not require dose adjustments for patients with **renal impairment**. However, patients with **significant renal disease** should be closely monitored for any adverse reactions, such as **proteinuria** or **renal toxicity**, during treatment.

Administration

Information not available